Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China

OBJECTIVE: The purpose of this study was to evaluate the cost-effectiveness of nivolumab plus chemotherapy vs. chemotherapy as first-line therapy in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma from the perspective of the Chinese healthcare system....

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Yamin, Ding, Yufeng, Zhang, Qilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065445/
https://www.ncbi.nlm.nih.gov/pubmed/35515123
http://dx.doi.org/10.3389/fonc.2022.851522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065445/
https://www.ncbi.nlm.nih.gov/pubmed/35515123
http://dx.doi.org/10.3389/fonc.2022.851522

Ejemplares similares